# Coherence Neuro Raises $45M Series A

> Coherence Neuro secures $45M Series A to build real-time cancer treatment systems using electrical biomarkers.
- Title: Coherence Neuro Raises $45M Series A · Pulse 2.0 | Shortify
- Summary: Coherence Neuro secures $45M Series A to build real-time cancer treatment systems using electrical biomarkers. Coherence Neuro raised $45 million to develop…
- Keywords: coherence neuro, series a, founders fund, openai startup fund, cancer monitoring, electrical biomarkers, glioblastoma, fda breakthrough device, startups, business, Coherence, Neuro
- Source: Pulse 2.0 — https://pulse2.com/coherence-neuro-raises-45-million-series-a-co-led-by-founders-fund-and-the-openai-startup-fund
- Author: Amit Chowdhry
- Published: 2026-10-28T12:33:10+00:00
- Read time: 1 min
- Topics: coherence neuro, series a, founders fund, openai startup fund, cancer monitoring, electrical biomarkers, glioblastoma, fda breakthrough device, startups, business
## Funding Round
Coherence Neuro raised $45 million Series A co-led by Founders Fund and The OpenAI Startup Fund.
## New Investors
New investors include Lux Capital, 8VC, Timeless, Olive Capital, Ahren, and Neuralink experts.
## Technology Approach
Coherence uses electrical biomarkers to track tumor growth via neural activity in preclinical models.
## Next Steps
Coherence plans first chronic human trial in glioblastoma and seeks FDA Breakthrough Device designation.
## Key takeaway

Coherence Neuro raised $45 million to develop adaptive cancer treatment systems that monitor and respond to tumors via real-time electrical signals.